Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02883426 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02883426 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1 participants.
The verdict
NCT02883426, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will evaluate the safety and immunogenicity of the H3N2v MN 2010/AA ca live attenuated influenza vaccine (H3N2v LAIV) in healthy children and adults, 6 to 26 years old.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)
- BIOLOGICAL H3N2v inactivated subvirion influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02883426
The ClinicalTrials.gov registry entry for NCT02883426 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02883426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02883426 about?
NCT02883426 is a clinical study titled "Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease". This study will evaluate the safety and immunogenicity of the H3N2v MN 2010/AA ca live attenuated influenza vaccine (H3N2v LAIV) in healthy children and adults, 6 to 26 years old.
What is the current status of trial NCT02883426?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2016-09.
What interventions are being tested in trial NCT02883426?
The interventions under investigation include: Placebo (BIOLOGICAL), H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV) (BIOLOGICAL), H3N2v inactivated subvirion influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02883426?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.